Efficacy of Ingelvac PRRS® MLV

Efficacy of Ingelvac PRRS® MLV against a heterologous PRRSV 1-7-4 RFLP challengeEfficacy of Ingelvac PRRS® MLV against a heterologous PRRSV 1-7-4 RFLP challenge Dr. Reid Philips, Boehringer Ingelheim Vetmedica, Inc, shares insights on the efficacy of Ingelvac PRRS® MLV against a heterologous PRRSV 1-7-4 RFLP challenge. Key findings include: Ingelvac PRRS® MLV demonstrated significant protection against a virulent PRRSv ‘174’ challenge: 1) Significant reduction in viremia, 2) Significant reduction in lung lesions, and 3) Significant improvement in Daily Gain. Also, Ingelvac PRRS® MLV continues to demonstrate cross protection against new-emerging field strains [video].